In summary, we speculate that IGFBP1 may cooperate with YTHDF1 to mediate methylation modification, thereby inhibiting the activation of DCs and cytotoxic T lymphocytes, hindering the anti-tumor immune response in tumors. This evidence concerns the gene IGFBP1 and neoplasm.